NephroGenex Announces Positive Results for QT Study of Pyridorin

RALEIGH, N.C.-- NephroGenex, Inc. (NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.

Pyridorin showed no effect on the QT/QTc interval at the expected therapeutic dose of 300 mg and at a higher dose of 1200 mg. In previous Phase 1 and Phase 2 studies, Pyridorin has shown no effect on the QT/QTc interval in patients with diabetic nephropathy.

NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease

REHOVOT, Israel, Dec. 30, 2014 -- NeuroDerm Ltd. (NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that continuous, subcutaneous delivery of the company's proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. These results suggest that the high dose version, ND0612H, intended for severe Parkinson's disease patients, may provide an effective therapy alternative to current treatments requiring surgery.

Microbix Reports Strong Growth in Revenue and Operating Profit in 2014

Announces Completion of First Phase of LumiSort™ Platform Development
TORONTO, Dec. 29, 2014  - Microbix Biosystems Inc. (TSX:MBX.TO ), an innovator of biological products and technologies, today reported financial results for its fourth quarter and its fiscal year ending September 30, 2014.

Full Year Financial Results
Microbix reported total revenue of $8,396,796 in 2014 compared to $7,574,593 in 2013, or an increase of 11%. Virology products revenue was $8,258,175 in 2014 compared to $6,584,844 in 2013, or an increase of 25%. Strong customer demand and a favourable currency impact are the main drivers of this growth. R&D contract revenue was $138,621 in 2014 compared to $989,749 in 2013, reflecting the termination of the Kinlytic® license agreement by Zydus Cadila in the first quarter.

ProMetic Enters Into Strategic Alliance with GENERIUM Pharmaceuticals

LAVAL, QUEBEC--(Dec 22, 2014) - ProMetic Life Sciences Inc. (PLI.TO)(PFSCF) -

• GENERIUM granted exclusive rights to ProMetic's Plasma Protein Purification System ("PPPS™) derived biopharmaceuticals for Russia and Commonwealth of Independent States ("CIS")
• US $17 million license and milestone fees, of which US $6 million is payable upfront
• GENERIUM to pay ProMetic mid-single digit royalties on sales of biopharmaceuticals in Russia and CIS
• GENERIUM to build and operate a PPPS™ based plasma purification facility to process up to 600,000 liters of plasma annually, in Russia, to manufacture therapeutics for the Russian and CIS markets
• GENERIUM to fund and conduct all required clinical trials in Russia
• GENERIUM and ProMetic create global partnership for the co-development and commercialization of two coagulation factors